Article Text
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMed
Context
Non-steroidal anti-inflammatory drugs (NSAID) are widely prescribed worldwide. However, NSAID use frequently accompanies gastrointestinal (GI) injury including complications such as bleeding and perforation. Therefore co-therapy with gastroprotective drugs especially for those at risk has been advocated in current guidelines1 in which proton-pump inhibitors (PPI) and misoprostol are recommended to reduce NSAID-induced gastroduodenal ulcers. Another approach is to use cyclooxygenase-2 (COX-2) specific inhibitors.1 The role of histamine-2 receptor antagonists (H2RAs), however, remains uncertain in this regard. The only H2RA that …
Footnotes
-
Competing interests KS has received research grants from Takeda Pharmaceuticals, Eisai Pharmaceuticals, Astellas Pharmaceuticals and Astra-Zeneca Japan. He is also a consultant for Takeda Pharmaceuticals and Astra-Zeneca Japan and has received lecture fees from Takeda Pharmaceuticals.